002620.KS Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 09:30):

Stats
Dzisiejszy wolumen	553 228
Średni wolumen	43 628.00
Kapitalizacja rynkowa	168.86B
EPS	KRW0 ( 2024-02-20 )
Następna data zysków	( KRW0 ) 2024-05-10
Last Dividend	KRW0 ( N/A )
Next Dividend	KRW0 ( N/A )
P/E	0
ATR14	KRW21.73 (0.20%)

Wolumen Korelacja

Długi: 0.26 (neutral)

Krótki: -0.21 (neutral)

Signal:(51.966) Neutral

Jeil Pharma Holdings Inc Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Jeil Pharma Holdings Inc Korelacja - Waluta/Towar

0.76
( moderate )

0.61
( weak )

0.73
( moderate )

-0.20
( neutral )

-0.48
( neutral )

Jeil Pharma Holdings Inc Finanse

Annual	2023
Przychody:	KRW794.71B
Zysk brutto:	KRW201.82B (25.40 %)
EPS:	KRW-1 058.54

FY	2023
Przychody:	KRW794.71B
Zysk brutto:	KRW201.82B (25.40 %)
EPS:	KRW-1 058.54

FY	2022
Przychody:	KRW792.96B
Zysk brutto:	KRW180.48B (22.76 %)
EPS:	KRW-5 416.22

FY	2021
Przychody:	KRW762.57B
Zysk brutto:	KRW180.51B (23.67 %)
EPS:	KRW-226.85

Financial Reports:

No articles found.

Jeil Pharma Holdings Inc

Jeil Pharma Holdings Inc manufactures and sells ingredients of drugs, incrementally modified drugs, and generic drugs in South Korea. The company offers active pharmaceutical ingredients in the areas of antibiotics, gastrointestinal, cardiovascular, neuropsychiatry, oncology, endocrinology, urology, antiviral, and antihistamines, as well as patch products. It also provides finished dosage forms in the areas of anti-bacteria and anti-fungal, anti-virus, cardiovascular, endocrinology, neurology, gastrointestinal, urology, oncology, anti-histamine, rheumatology, respiratory, otolaryngological, heaptic, laxatives, and purgatives. The company exports its products to approximately 40 countries in the Association of Southeast Asian Nations, Central and South America, Africa, etc. Jeil Pharma Holdings Inc was founded in 1959 and is headquartered in Seoul, South Korea.

Aktualne aktualizacje dla Jeil Pharma Holdings Inc [002620.KS]

Upcoming Earnings Alert